This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (117)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Psychopharmacology  • Psychiatry, Other  • Alert me on articles by topic

Anne T. Harvey, PhD; Richard L. Rudolph, MD; Sheldon H. Preskorn, MD

Arch Gen Psychiatry. 2000;57:503-509.

Background  Indirect evidence suggests that the antidepressant venlafaxine hydrochloride selectively inhibits serotonin (5-HT) uptake at low doses, whereas at high doses, it inhibits both 5-HT and norepinephrine (NE) uptake. We hypothesized that, in vivo, both high and low doses would inhibit the 5-HT uptake of platelets but that the higher dose would differentially blunt the pressor response to tyramine, a marker for NE uptake.

Methods  Healthy male volunteers aged 18 to 45 years received either 75 mg or 375 mg of venlafaxine hydrochloride per day, the 5-HT uptake inhibitor sertraline hydrochloride (50 mg/d), or the NE uptake inhibitor maprotiline hydrochloride (150 mg/d) (n=8 for each of 4 treatment groups). Changes in platelet 5-HT uptake and the pressor response to intravenous tyramine were assessed following the initial dose and after 1 and 2 weeks of drug administration.

Results  Platelet 5-HT uptake was inhibited by venlafaxine across the dose range and by sertraline but not maprotiline. Inhibition was competitive, related to increases in affinity and not related to capacity. Steady-state drug levels were associated with a 5-HT uptake inhibition of 87% or more in subjects taking venlafaxine or sertraline. The pressor response to tyramine differentially distinguished maprotiline from sertraline and the low dose of venlafaxine but not from the high dose of venlafaxine.

Conclusion  This study provides the first in vivo evidence in healthy humans that both 5-HT uptake and NE uptake inhibition are mechanisms of action sequentially engaged by venlafaxine over its clinically relevant dose range.

From the Psychiatric Research Institute and the Department of Psychiatry, University of Kansas School of Medicine, Wichita (Drs Harvey and Preskorn); and Wyeth-Ayerst Research, Philadelphia, Pa (Dr Rudolph). This study was sponsored by Wyeth-Ayerst Research, Philadelphia, Pa. The Psychiatric Research Institute has also received financial support on various occasions from each of the companies whose antidepressant products are referred to in this article.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hypotension caused by therapeutic doses of venlafaxine: case report and proposed pathophysiological mechanisms
Alexandrino-Silva et al.
J Psychopharmacol 2008;22:214-216.
ABSTRACT  

Differences in Brain Glucose Metabolism Between Responders to CBT and Venlafaxine in a 16-Week Randomized Controlled Trial
Kennedy et al.
Am. J. Psychiatry 2007;164:778-788.
ABSTRACT | FULL TEXT  

Venlafaxine for Treatment of Interferon Alfa-Induced Depression
Malek-Ahmadi and Prabhu
The Annals of Pharmacotherapy 2006;40:2075-2075.
FULL TEXT  

DOV 216,303, a "Triple" Reuptake Inhibitor: Safety, Tolerability, and Pharmacokinetic Profile
Beer et al.
J Clin Pharmacol 2004;44:1360-1367.
ABSTRACT | FULL TEXT  

Mechanisms for the Inhibition of Genital Vascular Responses by Antidepressants in a Female Rabbit Model
Angulo et al.
J. Pharmacol. Exp. Ther. 2004;310:141-149.
ABSTRACT | FULL TEXT  

Psychotherapy alone and combined with pharmacotherapy in the treatment of depression
de Jonghe et al.
Br. J. Psychiatry 2004;185:37-45.
ABSTRACT | FULL TEXT  

Novel Uses of Selective Serotonin Reuptake Inhibitors in Women
El-Ibiary and Lee
Journal of Pharmacy Practice 2003;16:191-199.
ABSTRACT  

Evaluating the relationship of high-dose venlafaxine prescribing to treatment-resistant depression
Thomas and Taylor
Psychiatr. Bull. 2003;27:93-95.
ABSTRACT | FULL TEXT  

Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health
Chial et al.
Am. J. Physiol. Gastrointest. Liver Physiol. 2003;284:G130-G137.
ABSTRACT | FULL TEXT  

Inhibition of Norepinephrine Uptake in Patients With Major Depression Treated With Paroxetine
Gilmor et al.
Am. J. Psychiatry 2002;159:1702-1710.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Venlafaxine-ECT Combination in Treatment-Resistant Depression
Gonzalez-Pinto et al.
J. Neuropsychiatry Clin. Neurosi. 2002;14:206-209.
ABSTRACT | FULL TEXT  

Flushing in a Menopausal Woman Taking Venlafaxine
GRADY-WELIKY and HARTMANN
Am. J. Psychiatry 2001;158:1330-1330.
FULL TEXT  

S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: I. Receptor Binding, Electrophysiological, and Neurochemical Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine
Millan et al.
J. Pharmacol. Exp. Ther. 2001;298:565-580.
ABSTRACT | FULL TEXT  

S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: II. Behavioral Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine
Millan et al.
J. Pharmacol. Exp. Ther. 2001;298:581-591.
ABSTRACT | FULL TEXT  

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
THASE et al.
Br. J. Psychiatry 2001;178:234-241.
ABSTRACT | FULL TEXT